SRTS President & General Counsel reports new 1,000-share stock buy
Rhea-AI Filing Summary
Sensus Healthcare, Inc. (SRTS) director and officer Michael Sardano reported a personal purchase of company stock. On 11/18/2025, he acquired 1,000 shares of common stock at a price of $3.80 per share, coded as a purchase transaction. Following this trade, he now beneficially owns 118,839 shares of Sensus Healthcare common stock with direct ownership.
Sardano is listed as a Director and as an Officer with the title President and General Counsel, indicating both governance and executive responsibilities at the company. This filing is made on Form 4, which reports changes in ownership of the company’s equity securities by insiders.
Positive
- None.
Negative
- None.
FAQ
What insider transaction did Sensus Healthcare (SRTS) report on this Form 4?
The Form 4 reports that Michael Sardano acquired 1,000 shares of Sensus Healthcare common stock on 11/18/2025 at a price of $3.80 per share.
Who is the reporting person in this Sensus Healthcare (SRTS) Form 4 filing?
The reporting person is Michael Sardano, who is identified as both a Director and an Officer of Sensus Healthcare, holding the title President and General Counsel.
How many Sensus Healthcare (SRTS) shares does Michael Sardano own after the reported transaction?
After the reported transaction, Michael Sardano beneficially owns 118,839 shares of Sensus Healthcare common stock with direct ownership.
What was the transaction code used in this Sensus Healthcare (SRTS) Form 4?
The transaction is coded as P in the Form 4, indicating a purchase of common stock.
Does this Sensus Healthcare (SRTS) Form 4 include any derivative securities transactions?
The provided excerpt shows no derivative securities reported in Table II, only a purchase of common stock in Table I.
Is the ownership reported by Michael Sardano in Sensus Healthcare (SRTS) direct or indirect?
The Form 4 indicates that the 118,839 shares of Sensus Healthcare common stock are held with direct (D) ownership.